JP2019519492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519492A5 JP2019519492A5 JP2018558733A JP2018558733A JP2019519492A5 JP 2019519492 A5 JP2019519492 A5 JP 2019519492A5 JP 2018558733 A JP2018558733 A JP 2018558733A JP 2018558733 A JP2018558733 A JP 2018558733A JP 2019519492 A5 JP2019519492 A5 JP 2019519492A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 113
- 239000000427 antigen Substances 0.000 claims description 112
- 102000036639 antigens Human genes 0.000 claims description 112
- 108091007433 antigens Proteins 0.000 claims description 112
- 210000004027 cell Anatomy 0.000 claims description 23
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 18
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 18
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 10
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 10
- 102000018697 Membrane Proteins Human genes 0.000 claims description 10
- 108010052285 Membrane Proteins Proteins 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 9
- 102000009027 Albumins Human genes 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 239000012636 effector Substances 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 5
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 5
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 5
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 5
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- -1 IgM antibody Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229940123751 PD-L1 antagonist Drugs 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333643P | 2016-05-09 | 2016-05-09 | |
| US62/333,643 | 2016-05-09 | ||
| PCT/US2017/031791 WO2017196867A1 (en) | 2016-05-09 | 2017-05-09 | Anti-pd-l1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519492A JP2019519492A (ja) | 2019-07-11 |
| JP2019519492A5 true JP2019519492A5 (https=) | 2020-06-18 |
| JP6979971B2 JP6979971B2 (ja) | 2021-12-15 |
Family
ID=58710168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558733A Active JP6979971B2 (ja) | 2016-05-09 | 2017-05-09 | 抗ｐｄ−ｌ１抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10954302B2 (https=) |
| EP (1) | EP3455257B1 (https=) |
| JP (1) | JP6979971B2 (https=) |
| KR (1) | KR102343742B1 (https=) |
| CN (1) | CN109311985B (https=) |
| AU (1) | AU2017264683B2 (https=) |
| CA (1) | CA3021669A1 (https=) |
| DK (1) | DK3455257T3 (https=) |
| ES (1) | ES2899361T3 (https=) |
| HU (1) | HUE055972T2 (https=) |
| IL (1) | IL262295B2 (https=) |
| PL (1) | PL3455257T3 (https=) |
| PT (1) | PT3455257T (https=) |
| SG (1) | SG11201809336QA (https=) |
| WO (1) | WO2017196867A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015023120A2 (pt) | 2013-03-15 | 2017-11-21 | Genentech Inc | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado |
| CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| EP3105250B1 (en) | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| SG11201809336QA (en) * | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| MX2019011986A (es) | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| MX2019012295A (es) | 2017-04-14 | 2020-02-07 | Tollnine Inc | Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso. |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| EP3710480A4 (en) * | 2017-11-17 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | SINGLE-DOMAIN ANTIBODIES AND VARIANTS OF THEM DIRECTED AGAINST PD-L1 |
| WO2019109974A1 (zh) * | 2017-12-06 | 2019-06-13 | 正大天晴药业集团南京顺欣制药有限公司 | 抗pd-l1抗体及其抗原结合片段 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| EP3741777A4 (en) * | 2018-01-10 | 2021-10-13 | Jiangsu Hengrui Medicine Co., Ltd. | PD-L1 ANTIBODIES, ANTIGIBODY FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF |
| US11078283B2 (en) * | 2018-01-17 | 2021-08-03 | Apexigen, Inc. | Anti-PD-L1 antibodies and methods of use |
| MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| TWI756621B (zh) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥（蘇州）有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
| EP3929213A4 (en) * | 2019-02-21 | 2023-03-08 | Eucure (Beijing) Biopharma Co., Ltd | Anti-pd-l1 antibody and use thereof |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| JP2022544405A (ja) * | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| CN110746493A (zh) * | 2019-09-06 | 2020-02-04 | 中国药科大学 | 一种pd-l1拮抗剂多肽及其应用 |
| CN113121686B (zh) * | 2019-12-31 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 抗pd-l1抗体及其应用 |
| CA3169523A1 (en) | 2020-02-28 | 2021-09-02 | Jaume Pons | Transglutaminase-mediated conjugation |
| EP4139362A2 (en) | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
| CN113754775A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pd-l1和her2的双特异性抗体 |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| WO2022026475A2 (en) * | 2020-07-27 | 2022-02-03 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| KR102863510B1 (ko) * | 2020-08-03 | 2025-09-23 | 난트셀, 인크. | Il-15 초작용제에 대한 약물-특이적 약동학 검정 (drug-specific pharmacokinetic assay for il-15 superagonist cross-reference to related applications) |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN113943371B (zh) * | 2021-11-01 | 2023-05-05 | 达石药业(广东)有限公司 | 一种抗her2/抗pd-l1双功能抗体及其应用 |
| WO2023178253A2 (en) * | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| CN120603849A (zh) * | 2023-01-18 | 2025-09-05 | 科望(苏州)生物医药科技有限公司 | 抗pdl1单域抗体、融合蛋白及其用途 |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| DK1814913T3 (en) | 2004-11-05 | 2015-09-28 | Univ Leland Stanford Junior | ANTIBODY-INDUCED CELL membrane damage. |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
| CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP3105250B1 (en) | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| JP6666905B2 (ja) | 2014-05-29 | 2020-03-18 | スプリング バイオサイエンス コーポレーション | Ｐｄ−ｌ１抗体及びその使用 |
| CN106604742B (zh) * | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| KR102476226B1 (ko) * | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3355913B1 (en) * | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| SG11201809336QA (en) * | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| AU2017299608A1 (en) | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric CD137/4-1BB binding molecules and uses thereof |
| JP2019530640A (ja) | 2016-07-20 | 2019-10-24 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体ｏｘ４０結合分子及びその使用 |
| MX2019000799A (es) | 2016-07-20 | 2019-06-03 | Igm Biosciences Inc | Moleculas de union a gitr multimericas y usos de las mismas. |
| EP3496536A4 (en) | 2016-07-20 | 2020-02-12 | IGM Biosciences, Inc. | MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF |
| MX2019011986A (es) | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| EP3759229A4 (en) | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| US20210380701A1 (en) | 2018-10-23 | 2021-12-09 | Igm Biosciences, Inc. | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
| US20220106398A1 (en) | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
-
2017
- 2017-05-09 SG SG11201809336QA patent/SG11201809336QA/en unknown
- 2017-05-09 PT PT177242633T patent/PT3455257T/pt unknown
- 2017-05-09 ES ES17724263T patent/ES2899361T3/es active Active
- 2017-05-09 IL IL262295A patent/IL262295B2/en unknown
- 2017-05-09 PL PL17724263T patent/PL3455257T3/pl unknown
- 2017-05-09 AU AU2017264683A patent/AU2017264683B2/en not_active Ceased
- 2017-05-09 CA CA3021669A patent/CA3021669A1/en active Pending
- 2017-05-09 US US16/098,479 patent/US10954302B2/en active Active
- 2017-05-09 JP JP2018558733A patent/JP6979971B2/ja active Active
- 2017-05-09 HU HUE17724263A patent/HUE055972T2/hu unknown
- 2017-05-09 WO PCT/US2017/031791 patent/WO2017196867A1/en not_active Ceased
- 2017-05-09 KR KR1020187035104A patent/KR102343742B1/ko active Active
- 2017-05-09 DK DK17724263.3T patent/DK3455257T3/da active
- 2017-05-09 EP EP17724263.3A patent/EP3455257B1/en active Active
- 2017-05-09 CN CN201780027997.1A patent/CN109311985B/zh active Active
-
2021
- 2021-02-10 US US17/172,790 patent/US20210163600A1/en not_active Abandoned
-
2023
- 2023-09-07 US US18/463,194 patent/US20240002514A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519492A5 (https=) | ||
| US12528879B2 (en) | Multi-specific binding proteins for cancer treatment | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| JP7809680B2 (ja) | 癌処置のための多重特異性結合タンパク質 | |
| US10604576B2 (en) | Antibodies and immunocytokines | |
| CN114716552B (zh) | 人源化、小鼠或嵌合抗cd47单克隆抗体 | |
| US20220227870A1 (en) | Triple-chain antibody, method for preparation and use thereof | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| EP3988568A1 (en) | Combination treatment | |
| EP3356401A1 (en) | Binding molecules with modified j-chain | |
| CA3015938A1 (en) | Anti-lag-3 antibodies | |
| JP2019524693A5 (https=) | ||
| US20240301085A1 (en) | Humanized gpc3 antibody and application thereof | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| KR20240049318A (ko) | Fap/cd40 결합 분자 및 이의 의학적 용도 | |
| JP2021512604A5 (https=) | ||
| CN114829405B (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| CN113811545B (zh) | 对btn2具有特异性的抗体及其用途 | |
| CN119053622A (zh) | 一种抗ceacam5和ceacam6抗体及其应用 | |
| JP2024522172A (ja) | ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック | |
| RU2802272C2 (ru) | Антитело к cd3 и его фармацевтическое применение | |
| HK40128404A (zh) | Trop2抗体 | |
| EA047971B1 (ru) | Dll3/cd3 связывающие белки для лечения рака |